Skip to main content

Heterogeneity Found in Appropriate Use Criteria for Imaging of CAD

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Aug. 23, 2023 -- U.S. Centers for Medicare & Medicaid Services (CMS)-qualified Appropriate Use Criteria (AUC) for imaging of coronary artery disease (CAD) are heterogeneous and discrepant, according to a study published online Aug. 22 in Annals of Internal Medicine.

David E. Winchester, M.D., from the University of Florida College of Medicine in Gainesville, and colleagues reviewed AUC published by CMS-qualified provider-led entities (PLEs) focusing on advanced imaging tests for CAD. Publicly available approved AUC with recommendations related to testing for CAD were included.

The researchers found that seven of the 17 CMS-qualified PLEs had published AUC relating to CAD. There was considerable variation in the methods and formatting of these AUCs. There was variation in the number of clinical scenarios covered, ranging from six to 210; the number of advanced imaging methods covered varied from one to 25. Many AUCs offered no guidance on appropriateness when specifically applied to clinical scenarios; those that did conflicted with respect to appropriateness.

"Substantial discrepancies in the scope, methods, and formatting of PLE-developed AUC for imaging in suspected CAD leave the AUC program vulnerable to clinician confusion and resistance possibly risking failure to achieve its intended effect on widespread clinical implementation," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.